- ►diabetesjournals.org LP Plotnick, LM Clark, FL Brancati, T Erlinger - Diabetes Care, 2003 - Am Diabetes Assoc RESULTS—There was a small but significant decrease in HbA 1c at 3–6 months
after pump start (7.7 vs. 7.5%; P = 0.03). HbA 1c levels then gradually
increased and remained elevated after 1 year of follow-up; however, this ... Cited by 146 - Related articles - BL Direct - All 10 versions
R Hovorka - Diabetic medicine, 2006 - duke.edu Background The last two decades have witnessed unprecedented technological
progress in the development of continuous glucose sensors, resulting in the
first generation of commercial glucose monitors. This has fuelled the ... Cited by 115 - Related articles - View as HTML - BL Direct - All 7 versions
DM Wilson, BA Buckingham, EL Kunselman, … - Diabetes Care, 2005 - care.diabetesjournals.org.p.angrylapdog.com RESULTS—The 19 subjects' ages ranged from 1.7 to 6.1 (mean 3.6) years,
duration of diabetes ranged from 0.6 to 2.6 (mean 1.4) years, and baseline HbA
1c ranged from 6.7 to 9.6% (mean 7.9%). Seven subjects were male. Nine ... Cited by 108 - Related articles - All 7 versions
- ►diabetesjournals.org [PDF] R Retnakaran, B Zinman - Diabetes Care, 2005 - Am Diabetes Assoc Cardiac ventricles release B-type na- triuretic peptide (BNP) in response to
volume expansion and pressure overload; therefore, BNP concentration may be used
as a biochemical marker of cardiac failure (1). BNP levels are high in ... Cited by 95 - Related articles - BL Direct - All 8 versions
SK McMahon, FL Airey, DA Marangou, KJ … - Diabetic Medicine, 2005 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 64 - Related articles - BL Direct - All 5 versions
JL Colquitt, C Green, MK Sidhu, D Hartwell, …, 2004 - nice.org.uk Page 1. Clinical and cost-effectiveness of CSII for diabetes - CONFIDENTAL
CLINICAL AND COST EFFECTIVENESS OF CONTINUOUS SUBCUTANEOUS ... Cited by 60 - Related articles - View as HTML - All 10 versions
RP Radermecker, AJ Scheen - Diabetes/Metabolism Reviews - interscience.wiley.com Portable insulin infusion devices are effective and safe insulin delivery
systems for managing diabetes mellitus, especially type 1 diabetes. Rapidly
absorbed insulin analogues, such as insulin lispro or insulin aspart, may ... Cited by 50 - Related articles - BL Direct - All 3 versions
- ►diabetesjournals.org IB Hirsch, BW Bode, S Garg, WS Lane, A … - Diabetes Care, 2005 - Am Diabetes Assoc RESULTS—Mean serum fructosamine levels were significantly lower after CSII
therapy than after MDI therapy (343 ± 47 vs. 355 ± 50 μmol/l, respectively; P
= 0.0001). Continuous glucose monitoring profiles over a 24-h time period ... Cited by 45 - Related articles - All 7 versions
P Scuffham, L Carr - Diabetic Medicine, 2003 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 44 - Related articles - BL Direct - All 7 versions
AH Barnett - Diabetic Medicine, 2003 - interscience.wiley.com Tight glycaemic control (ideally, HbA 1c < 7%) is central to reducing the risk
of long-term complications of diabetes. This approach, for both Type 1 and Type
2 diabetes, commonly involves the use of basal insulin, and must be ... Cited by 41 - Related articles - BL Direct - All 4 versions
